Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Between Bedside and Bench
  • Published:

Understanding Biomarkers of Neurodegeneration: Ultrasensitive detection techniques pave the way for mechanistic understanding

Nature Medicine volume 21, pages 217–219 (2015)Cite this article

Subjects

New methods for detecting indications of neurodegeneration are necessary to diagnose neurodegenerative diseases. In identifying suitable biomarkers that can be monitored by these techniques, the pathogenic mechanisms that lead to these diseases may also be elucidated.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Current and future biomarkers for Alzheimer disease (AD).

References

  1. Blennow, K., Hampel, H., Weiner, M. & Zetterberg, H. Nat. Rev. Neurol. 6, 131–144 (2010).

    Article  CAS  Google Scholar 

  2. Savage, M.J. et al. J. Neurosci. 34, 2884–2897 (2014).

    Article  CAS  Google Scholar 

  3. Hölttä, M. et al. PLoS ONE 8, e66381 (2013).

    Article  Google Scholar 

  4. Yang, T. et al. Alzheimers Dement. 9, 99–112 (2013).

    Article  Google Scholar 

  5. Rissin, D.M. et al. Nat. Biotechnol. 28, 595–599 (2010).

    Article  CAS  Google Scholar 

  6. Randall, J. et al. Resuscitation 84, 351–356 (2013).

    Article  CAS  Google Scholar 

  7. Zetterberg, H. et al. Alzheimers Res. Ther. 5, 9 (2013).

    Article  CAS  Google Scholar 

  8. Meredith, J.E. Jr. et al. PLoS ONE 8, e76523 (2013).

    Article  CAS  Google Scholar 

  9. Kvartsberg, H. et al. Alzheimers Dement. doi:10.1016/j.jalz.2014.10.009 (19 December 2014).

Download references

Author information

Authors and Affiliations

  1. Kaj Blennow and Henrik Zetterberg are at the Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.,

    Kaj Blennow

  2. Henrik Zetterberg is also at the University College London Institute of Neurology, Queen Square, London, UK.,

    Henrik Zetterberg

Authors
  1. Kaj Blennow
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Henrik Zetterberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kaj Blennow.

Ethics declarations

Competing interests

H.Z. and K.B. are listed as co-inventors on a US patent application (Q0052.70018US00) for plasma tau as a brain injury marker. K.B. has served on advisory boards for Eli Lilly, Kyowa Kirin Pharma, Pfizer and Roche. No other disclosures are reported.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Blennow, K., Zetterberg, H. Understanding Biomarkers of Neurodegeneration: Ultrasensitive detection techniques pave the way for mechanistic understanding. Nat Med 21, 217–219 (2015). https://doi.org/10.1038/nm.3810

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm.3810

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research